https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-july-24-2026/ 2026-07-24T21:24:29Z Pharminent en GLP-1 Competitive Market Digest • Weekly • July 24, 2026 2026-07-24T21:24:27Z Blog https://pharminent.com/d-c-circuit-affirms-hhs-authority-over-340b-rebate-models/ 2026-07-24T20:02:33Z Pharminent en D.C. Circuit Affirms HHS Authority Over 340B Rebate Models 2026-07-24T20:02:33Z Blog https://pharminent.com/ema-chmp-recommends-twelve-new-medicines-for-approval-at-july-2026-meeting/ 2026-07-24T20:03:11Z Pharminent en EMA CHMP Recommends Twelve New Medicines for Approval at July 2026 Meeting 2026-07-24T20:02:32Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-24-2026/ 2026-07-24T15:44:57Z Pharminent en Strategic News Watch • July 24, 2026 2026-07-24T15:44:55Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-july-24-2026/ 2026-07-24T14:20:36Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • July 24, 2026 2026-07-24T14:20:33Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-july-23-2026/ 2026-07-24T13:30:35Z Pharminent en Rare Disease & Gene Therapy Digest • July 23, 2026 2026-07-24T13:30:32Z Blog https://pharminent.com/lillys-retatrutide-hits-22-6-weight-loss-in-phase-3-but-cardiovascular-benefit-remains-elusive/ 2026-07-24T13:27:29Z Pharminent en Lilly's Retatrutide Hits 22.6% Weight Loss in Phase 3, But Cardiovascular Benefit Remains Elusive 2026-07-23T20:09:34Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-23-2026/ 2026-07-23T16:35:47Z Pharminent en Strategic News Watch • July 23, 2026 2026-07-23T16:35:45Z Blog https://pharminent.com/lilly-plans-q1-2027-filing-for-obesity-triple-retatrutide/ 2026-07-23T20:03:28Z Pharminent en Lilly plans Q1 2027 filing for obesity triple retatrutide 2026-07-23T12:38:01Z Blog https://pharminent.com/gsks-10-6b-nuvalent-bet-pays-off-early-as-fda-approves-lung-cancer-drug/ 2026-07-23T20:03:44Z Pharminent en GSK's $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug 2026-07-23T11:59:20Z Blog